Tesamorelin Peptide for Sale – Tesamorelin Peptide (GHRH Analog) – High Purity ≥99% | cGMP Grade for Metabolic & Endocrine Research

Tesamorelin Peptide (TH9507) is a synthetic 44-amino acid analog of human growth hormone-releasing hormone (GHRH 1-44). It is a potent, selective GHRH receptor agonist engineered for enhanced stability and bioactivity in metabolic research.

Tesamorelin is structurally identical to endogenous GHRH with a single modification: a trans-3-hexenoic acid group at the N-terminus. This modification confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation, significantly extending its research half-life to approximately 30-60 minutes.

Looking for Tesamorelin peptide for sale from a trusted supplier? Shanghai AmbioPharm, Inc. provides high purity Tesamorelin peptide manufactured under advanced, quality-controlled environments to support modern research applications. Tesamorelin is a synthetic peptide widely studied in metabolic and biochemical research, making it a valuable compound for scientific and biotech laboratories.

Our Tesamorelin peptide is synthesized using pharmaceutical-grade processes to ensure ≥99% purity, excellent stability, and consistent batch performance. Each order includes a Certificate of Analysis (COA), ensuring full transparency and verification of product quality. With our manufacturing facility in Shanghai and USA-based distribution support, we guarantee fast, secure shipping and reliable supply for both small-scale and bulk orders.

As a GHRH analog, Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating endogenous growth hormone (GH) release in a pulsatile manner. This physiological GH profile promotes IGF-1 production and downstream metabolic effects without the supraphysiological peaks associated with direct GH administration.

At Shanghai AmbioPharm, Inc., we supply high-purity Tesamorelin Peptide (≥99% by HPLC) for advanced metabolic and endocrine research. Our cGMP-grade material is synthesized in our FDA-inspected Shanghai facility and available for fast U.S. delivery from our Clearwater, South Carolina warehouse.

Key Product Details:

• Sequence: 44-amino acid GHRH analog (1-44) with N-terminal trans-3-hexenoic acid

• Code Name: TH9507

• CAS Number: 218949-48-5 (Tesamorelin acetate)

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₈S

• Molecular Weight: 5,135.9 g/mol

• Purity: ≥99% (HPLC)

• Form: Lyophilized white powder

• Storage: -20°C, protected from light, desiccated

• Grade Available: Non-GMP (R&D) and cGMP (clinical preparatory)

• Amino Acids: 44-mer (full-length GHRH 1-44)

• Key Modification: N-terminal trans-3-hexenoic acid (DPP-IV resistance)

• Research Half-Life: Approximately 30-60 minutes

• Receptor Target: GHRH receptor (GHRHR)

Why Choose AmbioPharm for Tesamorelin Peptide?

As a global peptide CDMO, AmbioPharm combines scientific expertise with large-scale manufacturing capabilities. Choosing our Tesamorelin peptide for sale ensures premium quality, trusted sourcing, and dependable delivery tailored to your research needs.

• ✅ FDA-inspected cGMP manufacturing

• ✅ Full Certificate of Analysis (COA) with each batch

• ✅ HPLC chromatogram and mass spec data included

• ✅ Verified DPP-IV resistance confirmation

• ✅ Low endotoxin levels (<1 EU/mg)

• ✅ U.S. warehousing – fast domestic shipping from South Carolina

• ✅ Batch-to-batch consistency for longitudinal metabolic studies

Research Applications:

• Growth hormone (GH) and IGF-1 axis research

• Metabolic and visceral adipose tissue studies

• HIV-associated lipodystrophy research models

• Endocrine function and pituitary research

• Age-related GH decline and sarcopenia models

• Bone density and metabolic health research

• Hepatic steatosis and lipid metabolism

• Cardiovascular risk marker research

Mechanism of Action:
Tesamorelin binds with high affinity to GHRH receptors on pituitary somatotroph cells, activating Gs proteins and adenylate cyclase. This increases intracellular cAMP, leading to PKA activation and GH gene transcription. The N-terminal trans-3-hexenoic acid modification prevents DPP-IV degradation, extending half-life compared to native GHRH. The result is pulsatile GH release that mimics physiological secretion patterns, stimulating hepatic IGF-1 production and downstream metabolic effects.

 Intended Use: For laboratory research purposes only. Not for human consumption or clinical use without regulatory approval.

Ordering Information:

• Minimum Order Quantity (MOQ): 5mg (R&D), 10g+ (cGMP bulk)

• Lead Time: 2-3 weeks (non-GMP), 6-8 weeks (cGMP)

• Shipping: From Clearwater, SC, USA (2-5 days domestic)